NCT05549635 (PFBIO-HP) is a clinical trial in Hypersensitivity Pneumonitis, sponsored by Nils Hoyer.

Who is sponsoring NCT05549635?

NCT05549635 is sponsored by Nils Hoyer.

What condition does NCT05549635 study?

NCT05549635 studies Hypersensitivity Pneumonitis.

Is NCT05549635 still recruiting?

NCT05549635 is currently recruiting now. Last updated 22 December 2023.

Last reviewed 2023-12-22 · How we verify

NCT05549635: PFBIO-HP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Database and Biobank of Patients With Hypersensitivity Pneumonitis

Recruiting now Last updated 22 December 2023

What this trial tests

trial in Hypersensitivity Pneumonitis in 50 participants. Currently enrolling.

Timeline

18 September 2022

Primary endpoint
31 December 2024

31 December 2028

Quick facts

Lead sponsor	Nils Hoyer
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	50
Start date	18 September 2022
Primary completion	31 December 2024
Estimated completion	31 December 2028
Sites	1 location across Denmark

Conditions studied

Hypersensitivity Pneumonitis — all drugs for Hypersensitivity Pneumonitis →

Sponsor

Nils Hoyer

Who can join

18 and older, any sex, with Hypersensitivity Pneumonitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sub-study of the main Pulmonary Fibrosis Biomarker (PFBIO) cohort (NCT02755441), recruiting patients with an MDT-diagnosis of hypersensitivity pneumonitis (HP). Patients are included for the collection of blood samples and regular clinical data. The database and biobank will be available for studies of HP, and can be directly compared to the main PFBIO cohort, which has recruited patients with Idiopathic pulmonary Fibrosis (IPF) since 2016. Biomarkers will be assessed as diagnostic and prognostic. Further subtyping of HP, based on blood markers (including precipitins) will also be possible with the PFBIO-HP project.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hypersensitivity Pneumonitis

Currently open trials in the same condition.

NCT03800017 — Skeletal Muscle Function in Interstitial Lung Disease · NA · recruiting
NCT05392881 — Interstitial Lung Disease Research Unit Biobank · recruiting
NCT04844359 — A Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05549635 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nils Hoyer
Last refreshed: 22 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05549635.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing